Tickborne SFTS Virus Vaccine Development

项目摘要/摘要 严重发热伴血小板减少综合征(SFTS)是一种新出现的由硬体动物传播的疾病。 由SFTS病毒(SFTSV)引起的传染病。SFTSV被列为最危险的病毒 世界卫生组织最有可能在不久的将来引起大范围流行病的病原体。的发病率。 猪瘟病毒感染人数不断增加，达到5000多人，死亡率高达 从12%到30%不等。SFTSV引起一种特征性的血小板减少症 与病毒性出血热非常相似。被感染的扁虱是人类流行性出血热病毒的主要来源 感染。特别是，这种扁虱最近在美国12个州的传播增加了这种可能性。 该疾病在远东以外地区的暴发。健康人群流行性出血热病毒感染的血清流行病学调查 不同年龄段的人没有显著差异，但临床诊断的SFTS患者有显著差异。 年龄大于~50岁，提示年龄是SFTS发病率和死亡率的关键危险因素。 目前还没有针对SFTSV的有效疫苗。这项提议的目标是 综合检测和比较四株猪瘟病毒的免疫原性和保护效果 在年龄依赖的雪貂模型中，针对致死性SFTSV感染的特定候选疫苗。

Project Summary/Abstract Severe fever with thrombocytopenia syndrome (SFTS) is a newly emerging tick-borne infectious disease caused by SFTS virus (SFTSV). SFTSV is listed in the most dangerous viral pathogens by the WHO that most likely cause wide epidemics in the near future. The incidence of SFTSV infection has continuously increased up to more than 5,000 humans with a mortality rate ranging from 12% to as high as 30%. SFTSV induces a characteristic thrombocytopenia that is remarkably similar to viral hemorrhagic fevers. Infected ticks are the major source of human SFTSV infection. Particularly, the recent spread of this tick to over 12 states of USA increases the potential for outbreaks of the disease beyond the Far East Asia. The sero-prevalence of SFTSV in healthy people is not significantly different among age groups, but clinically diagnosed SFTS patients are older than ~50 years, suggesting that age is the critical risk factor for SFTS morbidity and mortality. No effective vaccines are currently available for SFTSV. The goal of this proposal is to comprehensively test and compare the immunogenicity and protection efficacy of four SFTSV- specific vaccine candidates against lethal SFTSV infection in age-dependent ferret model.